Medical Device Makers Becton Dickinson & Co, Acquires Bard Medical for $24bn

24 April 2017

U.S medical technology giant Becton, Dickinson and Co have acquired their competitor C.R. Bard Inc. in a cash-and-stock deal worth a handsome $24 billion. The agreement sees Bard shares increase up to 20%.

Bard stockholders are expected to receive $223 in cash and a half share of BD stock for each Bard share they currently own. Bard stock closed last Friday at $253.07.

Becton, Dickinson and Co are expected to afford the deal with $1.7 billion cash, $10 billion of debt, $4.5 billion of equity and securities and $8 billion in company stock. The deal is expected to go through by the autumn following regulatory and shareholder approval.

Bard have been developing medical devices for more than 100 years offering products in the urology, oncology, vascular disease and surgical specialty areas.

What does this mean for Bard Employees?

Bard are a well-established company and acquisition means change. Employees can expect to see a change in the board and a company restructure to accommodate the new direction of the company. Company culture may be affected by uncertainty and after things begin to settle, take hold of the changing values and expectations at the top.

Have you been through a company take over? What changes would you expect from a move like this?

Nicola Lawler, Projectus Consulting